Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, María Trojano, Vincenzo Brescia Morra et al.|Brain|2020Cited by 90
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)Francesco Patti, Diego Centonze, Clara Grazia Chisari et al.|Multiple Sclerosis and Related Disorders|2020Cited by 33
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, María Trojano, Giuseppe Lucisano et al.|Multiple Sclerosis Journal|2022Cited by 11
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 10
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7